|
Liver diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |
|
Liver Dysfunction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
|
24076602 |
2013 |
|
Narcolepsy
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association database developed in the Japanese Integrated Database Project.
|
19629137 |
2009 |
|
Hypertensive disease
|
0.080 |
Biomarker
|
group |
BEFREE |
Together, our results demonstrated that DDAH1 plays an important role in attenuating monocrotaline-induced lung oxidative stress, pulmonary hypertension and RV hypertrophy in rats.
|
31402164 |
2019 |
|
Hypertensive disease
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Our results show that NRP1 is required for full expression of DDAH1 in endothelial cells and that NRP1 contributes to protection from low-dose angiotensin II-induced increases in blood pressure.-Wang, Y., Wang, E., Zhang, Y., Madamsetty, V. S., Ji, B., Radisky, D. C., Grande, J. P., Misra, S., Mukhopadhyay, D. Neuropilin-1 maintains dimethylarginine dimethylaminohydrolase 1 expression in endothelial cells, and contributes to protection from angiotensin II-induced hypertension.
|
30118322 |
2019 |
|
Hypertensive disease
|
0.080 |
GeneticVariation
|
group |
BEFREE |
The frequency of single nucleotide polymorphisms in arginase-1 (ARG1 rs2781666) and dimethylarginine dimethylaminohydrolase-1 (DDAH1 rs480414) genes has been found to differ in a cohort of bronchopulmonary dysplasia patients with pulmonary hypertension (cases) and without pulmonary hypertension (controls).
|
30267614 |
2018 |
|
Hypertensive disease
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Our results indicated that the C-allele of rs3087894 in DDAH1 was a risk factor for hypertension in the Kazakh group but a protective factor in the Uygur group.
|
26786611 |
2016 |
|
Hypertensive disease
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Furthermore, the DDAH1 and COL18A1 genes were associated with systolic BP change (P < 1.00 × 10(-6) and P = 4.00 × 10(-6), respectively), while EDNRA was associated with hypertension incidence (P = 2.39 × 10(-4)).
|
25424718 |
2015 |
|
Hypertensive disease
|
0.080 |
Biomarker
|
group |
BEFREE |
Regulation of DDAH1 by miR-21 plays a role in the development of hypoxia-induced pulmonary hypertension and may be of broader significance in pulmonary hypertension.
|
24895913 |
2014 |
|
Hypertensive disease
|
0.080 |
Biomarker
|
group |
BEFREE |
The lack of protection in cardiac and aortic tissues may be due to DDAH1 tissue selectivity and/or the extent of hypertension by the used combined model.
|
23110194 |
2012 |
|
Hypertensive disease
|
0.080 |
GeneticVariation
|
group |
BEFREE |
In that study a novel functional mutation of DDAH-1 was identified; the mutation carriers had a significantly elevated risk for cardiovascular disease and a tendency to develop hypertension.
|
16444868 |
2005 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
VEGF, HIF-1α and iNOS expression did not differ in DDAH1 mutant-positive tumors compared to control tumors, but was upregulated in wild-type DDAH1 overexpressing tumors.
|
29150732 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
However, overexpression of DDAH I had no measurable effect on tumour growth, vessel density, function or maturation.
|
29721731 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
DDAH-1 expression was significantly induced in primary HCC tumors compared to non-tumorous background liver.
|
28741166 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These findings suggest that DDAH1 functions as a tumor suppressor in GC and may be exploited as a diagnostic and prognostic biomarker for GC.
|
28580735 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We identified that DDAH1: -396_-395insGCGT insertion allele was significantly associated with increased risk of T2DM (discovery: adjusted odds ratio [OR] = 1.380, 95% CI = 1.128-1.687, p = .002; replication: OR = 1.231, 95% CI = 1.007-1.504, p = .043).
|
31733101 |
2020 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Circ-EZH2 knockdown reverses DDAH1 and CBX3-mediated cell growth and invasion in glioma through miR-1265 sponge activity.
|
31669648 |
2020 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Streptozotocin (STZ) was used to induce diabetes in adult DDAH1 knock-out and wild type mice.Healthy mice served as controls.
|
31818438 |
2019 |
|
Diabetes
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that inducible nitric oxide synthase/gamma-Glutamyl-cysteine ligase (iNOS/GGCL) and DDAH dysregulation may play a key role in high glucose mediated oxidative stress, whereas HO-1 inducers such as CAPE or its more potent derivatives may be useful in diabetes and other stress-induced pathological conditions.
|
31108850 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Streptozotocin (STZ) was used to induce diabetes in adult DDAH1 knock-out and wild type mice.Healthy mice served as controls.
|
31818438 |
2019 |